Patient and donor characteristics
| Characteristics . | No. patients . |
|---|---|
| Total patients in study | 510 |
| Median recipient age, y (range) | 38 (< 1-62) |
| Recipient age distribution, y | |
| 20 or younger | 144 |
| 21-30 | 63 |
| 31-40 | 85 |
| 41-50 | 144 |
| 51 or older | 74 |
| Sex, donor:recipient | |
| M:F | 112 |
| M:M | 190 |
| F:M | 101 |
| F:F | 107 |
| Median time from diagnosis to transplantation, mo (range) | 9 (< 1-246) |
| Etiology | |
| Idiopathic | 398 |
| Postradiation, chemotherapy, or both | 70 |
| Postaplastic anemia | 26 |
| Post-MPD (polycythemia vera, essential thrombocythemia) | 3 |
| Other disease | 4 |
| Unknown | 9 |
| Cytogenetics | |
| Normal | 126 |
| Abnormal | 238 |
| Failure/unknown | 146 |
| Recipient CMV serology | |
| Positive | 272 |
| Negative | 234 |
| Unknown | 4 |
| HLA-A, -B, -DRB1 matching | |
| HLA-A, -B, -DR identical | 376 |
| Allele potential identical | 24 |
| Mismatch | 110 |
| Preparative regimen | |
| TBI/CY ± other | 317 |
| BU/CY ± other | 128 |
| TBI/BU/CY | 18 |
| Other | 47 |
| GVHD prophylaxis | |
| T-cell depletion | 121 |
| CSA ± other | 326 |
| Other | 63 |
| Median cell dose (range) | |
| Non–T-cell depletion (× 108 nucleated cells/kg) | 2.9 (0.07-11.9) |
| T-cell depletion (× 108 nucleated cells/kg) | 0.8 (0.02-3.5) |
| Donor | |
| Median age, y (range) | 37 (19-59) |
| No. males | 302 |
| CMV seropositivity | 186 |
| Characteristics . | No. patients . |
|---|---|
| Total patients in study | 510 |
| Median recipient age, y (range) | 38 (< 1-62) |
| Recipient age distribution, y | |
| 20 or younger | 144 |
| 21-30 | 63 |
| 31-40 | 85 |
| 41-50 | 144 |
| 51 or older | 74 |
| Sex, donor:recipient | |
| M:F | 112 |
| M:M | 190 |
| F:M | 101 |
| F:F | 107 |
| Median time from diagnosis to transplantation, mo (range) | 9 (< 1-246) |
| Etiology | |
| Idiopathic | 398 |
| Postradiation, chemotherapy, or both | 70 |
| Postaplastic anemia | 26 |
| Post-MPD (polycythemia vera, essential thrombocythemia) | 3 |
| Other disease | 4 |
| Unknown | 9 |
| Cytogenetics | |
| Normal | 126 |
| Abnormal | 238 |
| Failure/unknown | 146 |
| Recipient CMV serology | |
| Positive | 272 |
| Negative | 234 |
| Unknown | 4 |
| HLA-A, -B, -DRB1 matching | |
| HLA-A, -B, -DR identical | 376 |
| Allele potential identical | 24 |
| Mismatch | 110 |
| Preparative regimen | |
| TBI/CY ± other | 317 |
| BU/CY ± other | 128 |
| TBI/BU/CY | 18 |
| Other | 47 |
| GVHD prophylaxis | |
| T-cell depletion | 121 |
| CSA ± other | 326 |
| Other | 63 |
| Median cell dose (range) | |
| Non–T-cell depletion (× 108 nucleated cells/kg) | 2.9 (0.07-11.9) |
| T-cell depletion (× 108 nucleated cells/kg) | 0.8 (0.02-3.5) |
| Donor | |
| Median age, y (range) | 37 (19-59) |
| No. males | 302 |
| CMV seropositivity | 186 |